COVID-19: Booster vaccines may warrant investigation in people on immunomodulatory therapy
medwireNews: Among people with immune-mediated diseases, COVID-19 vaccines have greater immunogenicity following the second compared with the first dose, and individuals with prior SARS-CoV-2 infection have robust antibody responses, research suggests.
Maria Prendecki (Imperial College London, UK) and colleagues evaluated immune responses to the Pfizer–BioNTech (BNT162b2) and Oxford–AstraZeneca (ChAdOx1 nCoV-2019) vaccines in a total of 140 individuals with immune-mediated diseases, most commonly anti-neutrophil cytoplasmic antibody-associated vasculitis or anti-glomerular basement membrane disease. Seroconversion data were available for 119 SARS-CoV-2 infection-naïve individuals after the first dose, and 91 people after the second dose.
In all, 28.6% of participants had detectable immunoglobulin G antibodies against the SARS-CoV-2 spike protein after the first vaccine dose, increasing to 59.3% after the second dose. A similar pattern of results was observed with cell-mediated immunity, with detectable T-cell responses seen in 26.0% and 82.6% after the first and second doses, respectively.
“Reassuringly, only 8.7% of infection-naïve patients had neither antibody nor T-cell responses detected following second-dose vaccine,” write Prendecki and team in the Annals of the Rheumatic Diseases.
Of note, all 19 individuals with prior SARS-CoV-2 infection had “robust serological responses” following the first vaccine dose, irrespective of immunotherapy use, they add.
Together, these findings suggest that “[a]dministration of additional vaccine (‘booster’) doses may be a potential strategy for serological non-responders,” conclude the researchers.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group
11 August 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.